These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38503890)

  • 41. Preoperative systemic immune-inflammation index predicts prognosis and guides clinical treatment in patients with non-small cell lung cancer.
    Yan X; Li G
    Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32175568
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immune Effective Score as a Predictor of Response to Neoadjuvant Trastuzumab Therapy and a Prognostic Indicator for HER2-Positive Breast Cancer.
    Wu X; Zhang C; Zhang H
    Curr Oncol; 2022 Jan; 29(1):283-293. PubMed ID: 35049700
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients.
    Ramić S; Paić F; Smajlbegović V; Perić Balja M; Hiršl L; Marton I; Knežević F
    Croat Med J; 2022 Apr; 63(2):126-140. PubMed ID: 35505646
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer: Role for Immune Monitoring.
    Datta J; Fracol M; McMillan MT; Berk E; Xu S; Goodman N; Lewis DA; DeMichele A; Czerniecki BJ
    JAMA Oncol; 2016 Feb; 2(2):242-6. PubMed ID: 26719971
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab.
    Palleschi M; Prochowski Iamurri A; Scarpi E; Mariotti M; Maltoni R; Mannozzi F; Barone D; Paganelli G; Casi M; Giampalma E; De Giorgi U; Rocca A
    Sci Rep; 2022 Mar; 12(1):3385. PubMed ID: 35233007
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients.
    Qin T; Yuan Z; Peng R; Bai B; Shi Y; Teng X; Liu D; Wang S
    Onco Targets Ther; 2013; 6():341-7. PubMed ID: 23630425
    [TBL] [Abstract][Full Text] [Related]  

  • 47. p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial.
    Sperinde J; Huang W; Vehtari A; Chenna A; Kellokumpu-Lehtinen PL; Winslow J; Bono P; Lie YS; Petropoulos CJ; Weidler J; Joensuu H
    Clin Cancer Res; 2018 Jul; 24(13):3046-3052. PubMed ID: 29535130
    [No Abstract]   [Full Text] [Related]  

  • 48. Identification of genetic and immune signatures for the recurrence of HER2-positive breast cancer after trastuzumab-based treatment.
    Xu C; Wang Y; Hong Y; Yao R; Wu L; Shen X; Qu Y; Zhang Z; Zhu W; Yang Y; Chen W; Zhou Y; Liang Z
    Breast Cancer Res Treat; 2023 Jun; 199(3):603-615. PubMed ID: 37084155
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
    Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
    Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic value of preoperative combined with postoperative systemic immune-inflammation index for disease-free survival after radical rectal cancer surgery: a retrospective cohort study.
    Sun J; Yang R; Wu H; Li L; Gu Y
    Transl Cancer Res; 2024 Jan; 13(1):371-380. PubMed ID: 38410202
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
    Luen SJ; Salgado R; Fox S; Savas P; Eng-Wong J; Clark E; Kiermaier A; Swain SM; Baselga J; Michiels S; Loi S
    Lancet Oncol; 2017 Jan; 18(1):52-62. PubMed ID: 27964843
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer.
    He X; Ji J; Tian M; Esteva FJ; Hortobagyi GN; Yeung SJ
    Clin Cancer Res; 2019 Dec; 25(24):7388-7395. PubMed ID: 31515457
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic significance of the skeletal muscle index and systemic inflammatory index in patients with lymph node-positive breast cancer after radical mastectomy.
    Tang R; Deng JP; Zhang L; Zhang WW; Sun JY; Chi F; Zhang J; Wu SG; He ZY
    BMC Cancer; 2022 Mar; 22(1):234. PubMed ID: 35241010
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increased systemic immune-inflammation index independently predicts poor survival for hormone receptor-negative, HER2-positive breast cancer patients.
    Sun Y; Li W; Li AJ; Su H; Yue J; Yu J
    Cancer Manag Res; 2019; 11():3153-3162. PubMed ID: 31114357
    [No Abstract]   [Full Text] [Related]  

  • 55. Baseline Lymphopenia: A Predictor Of Poor Outcomes In HER2 positive Metastatic Breast Cancer Treated With Trastuzumab.
    Che YQ; Zhang Y; Wang D; Liu HY; Shen D; Luo Y
    Drug Des Devel Ther; 2019; 13():3727-3734. PubMed ID: 31754298
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Correlation analysis between preoperative systemic immune inflammation index and prognosis of patients after radical gastric cancer surgery: based on propensity score matching method.
    Zhaojun X; Xiaobin C; Juan A; Jiaqi Y; Shuyun J; Tao L; Baojia C; Cheng W; Xiaoming M
    World J Surg Oncol; 2022 Jan; 20(1):1. PubMed ID: 34980151
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial.
    Lambertini M; Agbor-Tarh D; Metzger-Filho O; Ponde NF; Poggio F; Hilbers FS; Korde LA; Chumsri S; Werner O; Del Mastro L; Caparica R; Moebus V; Moreno-Aspitia A; Piccart MJ; de Azambuja E
    ESMO Open; 2020 Nov; 5(6):e000979. PubMed ID: 33154022
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
    van Ramshorst MS; van der Heiden-van der Loo M; Dackus GM; Linn SC; Sonke GS
    Breast Cancer Res Treat; 2016 Jul; 158(2):361-71. PubMed ID: 27357813
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pathologic Complete Response in HER2-Positive Breast Cancer Patients Receiving Trastuzumab in Neoadjuvant Setting.
    Sheikh F; Nazir A; Yasmeen S; Badar F; Ahmad U; Siddiqui N
    J Coll Physicians Surg Pak; 2019 Feb; 29(2):159-163. PubMed ID: 30700356
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer.
    Kogawa T; Fouad TM; Liu DD; Wu J; Shen Y; Masuda H; Fujii T; Chavez-MacGregor M; Alvarez RH; Hortobágyi GN; Valero V; Ueno NT
    Oncologist; 2016 Jan; 21(1):21-7. PubMed ID: 26659222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.